类乳腺癌易感基因BRCA1肽的设计、合成及与抑癌基因蛋白RAD51肽段的相互作用
收稿日期: 2017-08-21
修回日期: 2017-10-26
网络出版日期: 2017-10-31
基金资助
国家自然科学基金（Nos.21572046，21172054）资助项目.
Design and Synthesis of Breast Cancer Susceptibility Gene BRCA1 Analogs Peptides and the Interaction of Analogs Peptides with Breast Cancer Suppressor Gene Protein RAD51
Received date: 2017-08-21
Revised date: 2017-10-26
Online published: 2017-10-31
Supported by
Project supported by the National Natural Science Foundation of China (Nos. 21572046, 21172054).
乳腺癌易感基因BRCA1肽对抑制女性乳腺癌病发有积极作用，其与乳腺癌细胞内抑癌基因蛋白RAD51相互作用的研究是乳腺癌药物发现的重要部分.通过Discovery Studio模拟类BRCA1肽与RAD51对接过程，利用R-DOCK评价系统从结果中筛选出4条评分较高的类BRCA1肽，采用固相逐步合成法制得.通过荧光光谱、圆二色光谱等方法研究了其与RAD51肽段（Pep158-180、Pep181-200、Pep241-260）的相互作用，发现4条类BRCA1肽的作用都强于BRCA1肽，这与模拟的结果相一致，其中BRCA1-3与RAD51的两个关键肽段（Pep158-180、Pep241-260）的相互作用明显强于BRCA1肽和其他类肽.该研究结果为乳腺癌药物分子设计提供了依据.
李林璐, 吕名秀, 卢奎, 刘广斌, 彭露 . 类乳腺癌易感基因BRCA1肽的设计、合成及与抑癌基因蛋白RAD51肽段的相互作用[J]. 有机化学, 2018 , 38(1) : 246 -252 . DOI: 10.6023/cjoc201708041
Peptide breast cancer susceptibility gene BRCA1 plays an active role in inhibiting female breast cancer. The interaction between BRCA1 and breast cancer suppressor gene protein RAD51 in cancer cell is also an essential part for the treatment of breast cancer. Discovery Studio simulation of the docking process of BRCA1 analogs and RAD51 was used to screen the BRCA1 analogs with different charge and acid-base properties. The R-DOCK evaluation system is used to screened out 4 higher BRCA1 like peptides from the results, and the interactions with BRCA1 analogs of RAD51 peptides (Pep158-180, Pep181-200 and Pep241-260) were studied by using fluorescence spectroscopy and CD spectroscopy. The results indicate that acid-base properties of BRCA1 analogs have great influence on their interaction. The results showed that the effect of BRCA1-3 to RAD51 (Pep158-180/Pep241-260) which is the two key peptides were obviously higher than the other parent peptide. Besides, compared with BRCA1, all BRCA1 analogs combined with RAD51 much closer. The results provide evidence to design novel breast drugs for breast cancer.
Key words： BRCA1 peptide; RAD51 peptide; fluorescence; CD spectroscopy; DS simulation
[1] Qiu, J. J.; Hu, Z.; Guan, J. Q. Chin. Nurs. Res. 2017, 31, 303(in Chinese). (裘佳佳, 胡震, 管佳琴, 护理研究, 2017, 31, 303.)
[2] Li, H.; Zhao, W. J.;Cao, S. X.; Lu, K.; Zhao, Y. F. Chem. J. Chin. Univ. 2004, 25, 1866(in Chinese). (李红, 赵文杰, 曹书霞, 卢奎, 赵玉芬, 高等学校化学学报, 2004, 25, 1866.)
[3] Ma, L.; Zhao, D. X.; Ren, H. P.; Lu, K. Asian J. Chem. 2011, 23, 2020.
[4] Coquelle, N.; Green, R. Biochemistry 2011, 50, 4579.
[5] Raderschall, E.; Stout, K.; Freier, S. Cancer Res. 2002, 62, 219.
[6] Zhang, G.; Wang, L.; Zhou, X. J. Agric. Food Chem. 2014, 62, 991.
[7] Ito, M.; Yamamoto, S. Gene 2005, 7, 1044.
[8] Srishailam, A.; Kumar, Y. P.; Gabra, N. M.; Reddy, P. V.; Deepika, N.; Satyanarayana, S. J. Fluoresc. 2013, 23, 897.
[9] Henderson, B. R. Scientifica 2012, 796.
[10] Palma, P. N.; Krippahl, L.; Wampler, J. E. Proteins 2000, 39, 372.
[11] Taylor, J. S.; Burnett, R. M. Proteins 2000, 41, 173.
[12] Relles, H. M.; Schluenz, R. W. J. Org. Chem. 1972, 37, 1742.
[13] Hegde, A. H.; Prashanth, S. N.; Seetharamappa, J. J. Pharm. Biomed. 2012, 63, 40.
[14] Mazin, A. V.; Mazina, O. M.; Bugreev, D. V. DNA Repair 2010, 9, 286.
[15] Matuszak, N.; Muccioli, G. G.; Labar, G. J. Med. Chem. 2009, 52, 7410.
[16] Relles, H. M.; Schluenz, R. W. J. Org. Chem. 1972, 37, 1748.
[17] Shen, X.-C.; Liang, H.; He, X.-W.; Wang, X.-S. Chin. J. Anal. Chem. 2004, 32, 388(in Chinese). (沈星灿, 梁红, 何锡文, 王新省, 分析化学, 2004, 32, 388.)
[18] Zheng, T.; Wang, Z.-Y.; Hou, R.-B.; Shen, X.-C. J. Guangxi Nomal Univ. (Nat. Sci. Ed.) 2008, 26, 57(in Chinese). (郑婷, 王卓渊, 侯若冰, 沈星灿, 广西师范大学学报(自然科学版), 2008, 26, 57.)
[19] Xu, G, He, Q.; Yang, B. Lett. Drug Des. 2009, 6, 51.
[20] Viljakainen, L.; Pamilo, P. J. Mol. Evol. 2008, 67, 643.
[21] Gajski, G.; Garaj, K.; Vrhovac, V. Environ. Toxicol. Pharmacol. 2013, 36, 697.
[22] Zhen, Q.; Cheng, X. D. J. Mol. Biol. 2009, 393, 191.
[23] Li, B. Q. Peptide Drugs Research and Development, Beijing People's Medical Publishing House, Beijing, 2011, p. 37(in Chinese). (厉保秋, 多肽药物研究与开发, 人民卫生出版社, 北京, 2011, p. 37.)
[24] Zhao, D.-X.; Sun, J.; Lu, K. Chem. J. Chin. Univ. 2013, 34, 2114(in Chinese). (赵东欣, 孙静, 卢奎, 高等学校化学学报, 2013, 34, 2114.)
/
| 〈 |
|
〉 |
